| Originator: |
|
DHSC & NHS England and Improvement: Supply disruption alert
|
|
|
|
- Care Trusts
- Mental Health Trusts
- Specialists Trusts
- Learning Disabilities Trusts
- Mental Health & Social Care Trusts
- Ambulance Trusts
- Mental Health & Learning Disabilities Trusts
- Acute Trusts
- Community Trusts
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- DHSC Supply Disruption - Medicines
|
| Title: |
|
Neuromuscular blocking agents: atracurium, cisatracurium and rocuronium
|
| Broadcast content: |
|
SDA/2020/004 was issued this morning. We are reissuing this
as there are changes to the advice, as highlighted in the attached alert.
|
There are now limited supplies of atracurium injection
(all strengths) and cisatracurium injection (all strengths) remaining in the
system due to the recent increase in demand.
This alert contains advice on the management of affected
patients.
Given the links to covid-19 we have sent this alert to a
broader mailing list than would usually receive a Supply Disruption Alert of
this type.
Please note that no response is required via the CAS
website to this alert.
|
|
| Additional information: |
|
This alert is not relevant to primary care.
|